BDSI BioDelivery Sciences International Inc.

BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018

BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018

RALEIGH, N.C., July 24, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close of the U.S. Financial markets on Thursday, August 9, 2018. The company will host a conference call at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial In & Webcast Information:

Date:Thursday, August 9, 2018
Time:4:30pm Eastern Time
Domestic:800-458-4121
International:323-794-2093
Passcode:2839790
Webcast:
  
Replays available through August 23, 2018

Domestic:844-512-2921
International:412-317-6671
Conference ID:   2839790

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina. 

For more information, please visit or follow us:

Internet:
Facebook:     
Twitter:

© 2018 BioDelivery Sciences International, Inc. All rights reserved.

CONTACTS:

Mary Coleman

Vice President, Investor & Public Relations

919-582-9050

Monique Kosse

Managing Director

LifeSci Advisors

212-915-3820

EN
24/07/2018

Underlying

Reports on BioDelivery Sciences International Inc.

 PRESS RELEASE

BioDelivery Sciences International Announces ELYXYB™ is Now Available ...

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availa...

 PRESS RELEASE

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 Transaction expected to close late in the first quarter of 2022 RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic...

 PRESS RELEASE

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year...

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of

BIODELIVERY SCIENCES sees an upgrade to Slightly Positive due to a bet...

The general evaluation of BIODELIVERY SCIENCES (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 21, 2021, the closing pric...

 PRESS RELEASE

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining ...

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032 RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. District Court of Delaware has issued an opinion in favor of BDSI in the company’s patent litigation against Alvogen Group, Inc. and its affiliates, who filed an Abbreviated New Drug Application (ANDA) for BDSI’s BELBUCA® prod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch